Novo Nordisk’s Wegovy sales hit by competition from Eli Lilly
Novo is vying with Indianapolis-based Lilly for supremacy in the pharmaceutical industry’s fastest-growing new business, obesity drugs. The market is expected to reach $130 billion by the end of the decade.